GRAIL Announces FDA Advisory Committee Meeting to Review Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test
AdComGalleriPositive
AI Analysis
Summary
GRAIL announced that the FDA Molecular and Clinical Genetics Panel will hold an advisory committee meeting to review the Premarket Approval Application for the Galleri multi-cancer early detection test.
Outcome Details
FDA Advisory Committee meeting scheduled to review Premarket Approval Application
Importance:8/10
Sentiment:
0.40
FDAAdvisory CommitteePMAMedical DeviceCancer Detection
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on August 7, 2026 3:05 PM